Skip to main content
NCD 190.19 · version 1 · Laboratory NCD

NCD 190.19: Collagen Crosslinks, any Method

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.19

Benefit category
Diagnostic Laboratory Tests
Effective date
11/25/2002
Implemented 01/01/2003
Transmittal
Transmittal 17
Versions published
1
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
289 covered ICD-10
233 non-covered

TL;DR

NCD 190.19 sets Medicare's national policy for collagen crosslinks, any method under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. Generally speaking, collagen crosslink testing is useful mostly in "fast losers" of bone. The age when these bone markers can help direct therapy is often pre-Medicare. By the time a fast loser of bone reaches age 65, she will most likely have been stabilized… As a laboratory NCD it carries a national ICD-10 edit list: 289 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.

Item or service described

Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provide a quantitative measurement of bone resorption. Elevated levels of urinary collagen crosslinks indicate elevated bone resorption. Elevated bone resorption contributes to age-related and postmenopausal loss of bone leading to osteoporosis and increased risk of fracture. The collagen crosslinks assay can be performed by immunoassay or by high performance liquid chromatography (HPLC). Collagen crosslink immunoassays measure the pyridinoline crosslinks and associated telopeptides in urine.

Bone is constantly undergoing a metabolic process called turnover or remodeling. This includes a degradation process, bone resorption, mediated by the action of osteoclasts, and a building process, bone formation, mediated by the action of osteoblasts. Remodeling is required for the maintenance and overall health of bone and is tightly coupled; that is, resorption and formation must be in balance. In abnormal states of bone remodeling, when resorption exceeds formation, it results in a net loss of bone. The measurement of specific, bone-derived resorption products provides analytical data about the rate of bone resorption.

Osteoporosis is a condition characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased susceptibility to fractures of the hip, spine, and wrist. The term primary osteoporosis is applied where the causal factor in the disease is menopause or aging. The term secondary osteoporosis is applied where the causal factor is something other than menopause or aging, such as long-term administration of glucocorticosteroids, endocrine-related disorders (other than loss of estrogen due to menopause), and certain bone diseases such as cancer of the bone.

With respect to quantifying bone resorption, collagen crosslink tests can provide adjunct diagnostic information in concert with bone mass measurements. Bone mass measurements and biochemical markers may have complementary roles to play in assessing effectiveness of osteoporosis treatment. Proper management of osteoporosis patients, who are on long-term therapeutic regimens, may include laboratory testing of biochemical markers of bone turnover, such as collagen crosslinks, that provide a profile of bone turnover responses within weeks of therapy. Changes in collagen crosslinks are determined following commencement of antiresorptive therapy. These can be measured over a shorter time interval, such as three months, when compared to bone mass density. If bone resorption is not elevated, repeat testing is not medically necessary.

Indications and limitations of coverage

Indications

Generally speaking, collagen crosslink testing is useful mostly in "fast losers" of bone. The age when these bone markers can help direct therapy is often pre-Medicare. By the time a fast loser of bone reaches age 65, she will most likely have been stabilized by appropriate therapy or have lost so much bone mass that further testing is useless. Coverage for bone marker assays may be established, however, for younger Medicare beneficiaries and for those men and women who might become fast losers because of some other therapy such as glucocorticoids. Safeguards should be incorporated to prevent excessive use of tests in patients for whom they have no clinical relevance.

Collagen crosslinks testing is used to:

• Identify individuals with elevated bone resorption, who have osteoporosis in whom response to treatment is being monitored;

• Predict response (as assessed by bone mass measurements) to FDA approved antiresorptive therapy in postmenopausal women; and

• Assess response to treatment of patients with osteoporosis, Paget's disease of the bone, or risk for osteoporosis where treatment may include FDA approved antiresorptive agents, anti-estrogens or selective estrogen receptor moderators.

Limitations

Because of significant specimen to specimen collagen crosslink physiologic variability (15-20%), current recommendations for appropriate utilization include: one or two base-line assays from specified urine collections on separate days; followed by a repeat assay about three months after starting anti-resorptive therapy; followed by a repeat assay in 12 months after the three-month assay; and thereafter not more than annually, unless there is a change in therapy in which circumstance an additional test may be indicated three months after the initiation of new therapy.

Some collagen crosslink assays may not be appropriate for use in some disorders, according to FDA labeling restrictions.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.19 version 1. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 289 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.19
CodeCode set
82523CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $18.68, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.19 edits, October 2026
CodeCLFS amountWith QWPricing
82523$18.68$18.68national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 289 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.19 (sample)
ICD-10-CMDescriptionEffective
C44.1321Sebaceous cell carcinoma of skin of right upper eyelid, including canthus2018-10-01
C44.1322Sebaceous cell carcinoma of skin of right lower eyelid, including canthus2018-10-01
C44.1391Sebaceous cell carcinoma of skin of left upper eyelid, including canthus2018-10-01
C44.1392Sebaceous cell carcinoma of skin of left lower eyelid, including canthus2018-10-01
E05.00Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm2015-10-01
E05.01Thyrotoxicosis with diffuse goiter with thyrotoxic crisis or storm2015-10-01
E05.10Thyrotoxicosis with toxic single thyroid nodule without thyrotoxic crisis or storm2015-10-01
E05.11Thyrotoxicosis with toxic single thyroid nodule with thyrotoxic crisis or storm2015-10-01
E05.20Thyrotoxicosis with toxic multinodular goiter without thyrotoxic crisis or storm2015-10-01
E05.21Thyrotoxicosis with toxic multinodular goiter with thyrotoxic crisis or storm2015-10-01
E05.30Thyrotoxicosis from ectopic thyroid tissue without thyrotoxic crisis or storm2015-10-01
E05.31Thyrotoxicosis from ectopic thyroid tissue with thyrotoxic crisis or storm2015-10-01
E05.40Thyrotoxicosis factitia without thyrotoxic crisis or storm2015-10-01
E05.41Thyrotoxicosis factitia with thyrotoxic crisis or storm2015-10-01
E05.80Other thyrotoxicosis without thyrotoxic crisis or storm2015-10-01
E05.81Other thyrotoxicosis with thyrotoxic crisis or storm2015-10-01
E05.90Thyrotoxicosis, unspecified without thyrotoxic crisis or storm2015-10-01
E05.91Thyrotoxicosis, unspecified with thyrotoxic crisis or storm2015-10-01
E06.3Autoimmune thyroiditis2015-10-01
E07.9Disorder of thyroid, unspecified2015-10-01
E21.0Primary hyperparathyroidism2015-10-01
E21.1Secondary hyperparathyroidism, not elsewhere classified2015-10-01
E21.2Other hyperparathyroidism2015-10-01
E21.3Hyperparathyroidism, unspecified2015-10-01
E28.310Symptomatic premature menopause2015-10-01
E28.319Asymptomatic premature menopause2015-10-01
E28.39Other primary ovarian failure2015-10-01
E28.8Other ovarian dysfunction2015-10-01
E28.9Ovarian dysfunction, unspecified2015-10-01
E55.9Vitamin D deficiency, unspecified2015-10-01
E58Dietary calcium deficiency2015-10-01
E59Dietary selenium deficiency2015-10-01
E60Dietary zinc deficiency2015-10-01
E61.0Copper deficiency2015-10-01
E61.1Iron deficiency2015-10-01
E61.2Magnesium deficiency2015-10-01
E61.3Manganese deficiency2015-10-01
E61.4Chromium deficiency2015-10-01
E61.5Molybdenum deficiency2015-10-01
E61.6Vanadium deficiency2015-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.19 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release made no change to this NCD's ICD-10-CM list: no code was added, removed or given a new result against January 2026.

Codes on this NCD's list by release: October 2025: 522 · January 2026: 522 · October 2026: 522. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Revision history

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.19

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.19

What does NCD 190.19 cover?

Generally speaking, collagen crosslink testing is useful mostly in "fast losers" of bone. The age when these bone markers can help direct therapy is often pre-Medicare. By the time a fast loser of bone reaches age 65, she will most likely have been stabilized by appropriate therapy or have lost so much bone mass that further testing is useless. Coverage for bone marker assays may be established, however, for younger… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.19 take effect?

The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.

Does a Local Coverage Determination override NCD 190.19?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.19?

The October 2026 laboratory NCD edit list contains 289 ICD-10-CM codes that support collagen crosslinks, any method (for example C44.1321 Sebaceous cell carcinoma of skin of right upper eyelid, including canthus; C44.1322 Sebaceous cell carcinoma of skin of right lower eyelid, including canthus; C44.1391 Sebaceous cell carcinoma of skin of left upper eyelid, including canthus) and 233 codes that deny. The list applies to 82523.

How often does the lab NCD code list for 190.19 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.